Academic Report
Report Title: Sustainable Supply and Development of Rare Traditional Chinese Medicine Resources Based on Microbial Cell Factories
Reporter:Hu Yating, Professor
Capital University of Medical Sciences
Time:2026.11.06 Afternoon 15:00-17:00
Location:Room 702, High-Tech Building
Report Summary:
The sustainable supply of Traditional Chinese Medicine (TCM) resources is the cornerstone for promoting high-quality development of TCM. Against the backdrop of increasingly fragmented drug supply chains affected by climate and other factors, finding sustainable alternatives to Chinese medicinal resources (especially rare ones) and breaking excessive dependence on wild resources is crucial to ensuring medication safety. Building high-yield microbial cell factories using synthetic biology technology is one of the key means to alleviate the increasing depletion of natural resources and achieve sustainable resource utilization. Saccharomyces cerevisiae is widely used for the reconstruction of synthetic pathways and industrial-scale production of high value-added compounds such as natural products of traditional Chinese medicine, due to its clear cytogenetic background, simple genetic manipulation, and robustness. This report will use rare Chinese medicine derivatives derived from the Cyphyllum toxin and Tristanium trigon as examples to introduce how to efficiently produce complex active ingredients in Chinese medicines in microorganisms through multiple strategies; By using synthetic biotechnology, trace components in Trigonidium can be obtained, aiding the development of new drugs for treating rheumatoid arthritis.
Presenter Introduction:
Hu Yating, Professor at the College of Traditional Chinese Medicine, Capital Medical University, PI of the Laboratory of Synthetic Biology of Traditional Chinese Medicine, Deputy Director of the National Key Laboratory of TCM Quality Assurance and Sustainable Resource Utilization, and recipient of the National Overseas High-Level Young Talent Recruitment Program. The research group primarily focuses on the molecular mechanisms of active component formation in traditional Chinese medicine and its efficient biomanufacturing. Published multiple papers in international journals such as Science, Nature Catalysis, PNAS, JACS, and Green Chemistry. First constructed the microbial cell factory for KH617, an active component of anti-tumor traditional Chinese medicine, which received clinical trial approval in China and the United States. Applied for two international patents. Awarded the First Prize of Science and Technology by the China Association of Integrative Medicine.
Beijing University of Chemical Technology Key Laboratory of Effective Utilization of Chemical Resources in China
College of Life Sciences and Technology, Beijing University of Chemical Technology
Professor Yuan Qipeng's Research Group
